Market Overview:
The global liposomes drug delivery market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of cancer and other chronic diseases, rising demand for targeted drug delivery systems, and technological advancements in the field of liposomes drug delivery. Based on type, the global liposomes drug delivery market is segmented into liposomal doxorubicin, liposomal amphoteracin B, liposomal paclitaxel, and others. The others segment includes other types of lipid-based nanoparticles used for delivering drugs to target tissues or organs. Liposomal doxorubicin is expected to be the fastest-growing segment during the forecast period owing to its high efficacy in treating various types of cancers such as ovarian cancer, breast cancer, and leukemia. Based on application, the global liposomes drug delivery market is divided into fungal infection therapy, cancer & tumor therapy,, and others (cardiovascular disorders treatment etc.). Cancer & tumor therapy currently dominates this market owing to rising incidence rates of various types if cancers across all regions worldwide.
Product Definition:
Liposomes Drug Delivery is a technology used to deliver drugs and other therapeutic agents to specific tissues or organs. By using liposomes, which are tiny vesicles made of lipid (fat) molecules, drug delivery can be targeted more effectively than with traditional drug administration methods. This improved targeting may result in fewer side effects and increased effectiveness of the therapy.
Liposomal Doxorubicin:
Liposomal doxorubicin, a lipophilic drug is encapsulated in phospholipid vesicles. The drug is used as an anti-cancer agent and has shown efficacy against breast cancer cells (estrogen receptor positive). It has also been reported to be effective in the treatment of prostate cancer cells (androgen receptor positive).
Liposomal Amphoteracin B:
Liposomal amphotericin B is a lipophilic drug that can cross the blood-brain barrier and enter target cells. It has been used as an anti-fungal medication for the treatment of fungal infections, such as ringworm, athlete's foot, and jock itch.
Application Insights:
The others application segment held the largest share of more than 50.0% in 2017. The major applications of these vesicles include drug delivery for cardiovascular, gastrointestinal, respiratory and urological conditions among others. In addition to their wide therapeutic index, liposomes are used for non-invasive medical procedures such as gene therapy and vaccine delivery which is expected to propel the demand over the forecast period.
Fungal infection therapy is estimated to be one of the fastest growing segments owing to increasing prevalence of fungal infections coupled with unmet needs regarding antifungal drugs across various regions including Europe and North America.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a substantial number of key players and increasing R&D activities. The region is expected to maintain its dominance over the forecast period due to increasing incidence rates of cancer and other diseases, which can be treated effectively with liposomal drugs.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising disposable income, expanding patient pool, growing awareness about advanced therapies & vaccines among people living in emerging economies such as India & China. Moreover, government initiatives for improving healthcare infrastructure are also likely boost regional growth during the forecast period.
Growth Factors:
- Increasing demand for minimally invasive and non-invasive treatments
- Rising prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases
- Growing number of clinical trials for liposomes drug delivery therapies
- Technological advancements in the field of liposomes drug delivery
- Rising healthcare expenditure
Scope Of The Report
Report Attributes
Report Details
Report Title
Liposomes Drug Delivery Market Research Report
By Type
Liposomal Doxorubicin, Liposomal Amphoteracin B, Liposomal Paclitaxel, Others
By Application
Fungal Infection Therapy, Cancer & Tumor Therapy, Others
By Companies
Gilead Sciences, Pacira, Sun Pharmaceutical, Johnson & Johnson, Luye Pharma, Sigma-Tau Group, Ipsen (Onivyde), CSPC, Teva Pharmaceutical, Novartis, Fudan-Zhangjiang
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Liposomes Drug Delivery Market Report Segments:
The global Liposomes Drug Delivery market is segmented on the basis of:
Types
Liposomal Doxorubicin, Liposomal Amphoteracin B, Liposomal Paclitaxel, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Fungal Infection Therapy, Cancer & Tumor Therapy, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Gilead Sciences
- Pacira
- Sun Pharmaceutical
- Johnson & Johnson
- Luye Pharma
- Sigma-Tau Group
- Ipsen (Onivyde)
- CSPC
- Teva Pharmaceutical
- Novartis
- Fudan-Zhangjiang
Highlights of The Liposomes Drug Delivery Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Liposomal Doxorubicin
- Liposomal Amphoteracin B
- Liposomal Paclitaxel
- Others
- By Application:
- Fungal Infection Therapy
- Cancer & Tumor Therapy
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Liposomes Drug Delivery Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Liposomes are small, water-soluble spheres that can be used to deliver drugs and other substances into cells. Liposomes are formed from a liquid lipid (fat) mixture and a surfactant. The lipids are arranged in such a way that they form an oil-in-water emulsion. This type of emulsion is stabilized by the presence of the surfactant, which allows it to remain in suspension for extended periods of time. Once the liposomes have been formed, they can be loaded with drug or other substance and then injected into the body.
Some of the key players operating in the liposomes drug delivery market are Gilead Sciences, Pacira, Sun Pharmaceutical, Johnson & Johnson, Luye Pharma, Sigma-Tau Group, Ipsen (Onivyde), CSPC, Teva Pharmaceutical, Novartis, Fudan-Zhangjiang.
The liposomes drug delivery market is expected to register a CAGR of 10.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Liposomes Drug Delivery Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Liposomes Drug Delivery Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Liposomes Drug Delivery Market - Supply Chain
4.5. Global Liposomes Drug Delivery Market Forecast
4.5.1. Liposomes Drug Delivery Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Liposomes Drug Delivery Market Size (000 Units) and Y-o-Y Growth
4.5.3. Liposomes Drug Delivery Market Absolute $ Opportunity
5. Global Liposomes Drug Delivery Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Liposomes Drug Delivery Market Size and Volume Forecast by Type
5.3.1. Liposomal Doxorubicin
5.3.2. Liposomal Amphoteracin B
5.3.3. Liposomal Paclitaxel
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Liposomes Drug Delivery Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Liposomes Drug Delivery Market Size and Volume Forecast by Application
6.3.1. Fungal Infection Therapy
6.3.2. Cancer & Tumor Therapy
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Liposomes Drug Delivery Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Liposomes Drug Delivery Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Liposomes Drug Delivery Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Liposomes Drug Delivery Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Liposomes Drug Delivery Demand Share Forecast, 2019-2026
9. North America Liposomes Drug Delivery Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Liposomes Drug Delivery Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Liposomes Drug Delivery Market Size and Volume Forecast by Application
9.4.1. Fungal Infection Therapy
9.4.2. Cancer & Tumor Therapy
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Liposomes Drug Delivery Market Size and Volume Forecast by Type
9.7.1. Liposomal Doxorubicin
9.7.2. Liposomal Amphoteracin B
9.7.3. Liposomal Paclitaxel
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Liposomes Drug Delivery Demand Share Forecast, 2019-2026
10. Latin America Liposomes Drug Delivery Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Liposomes Drug Delivery Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Liposomes Drug Delivery Market Size and Volume Forecast by Application
10.4.1. Fungal Infection Therapy
10.4.2. Cancer & Tumor Therapy
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Liposomes Drug Delivery Market Size and Volume Forecast by Type
10.7.1. Liposomal Doxorubicin
10.7.2. Liposomal Amphoteracin B
10.7.3. Liposomal Paclitaxel
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Liposomes Drug Delivery Demand Share Forecast, 2019-2026
11. Europe Liposomes Drug Delivery Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Liposomes Drug Delivery Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Liposomes Drug Delivery Market Size and Volume Forecast by Application
11.4.1. Fungal Infection Therapy
11.4.2. Cancer & Tumor Therapy
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Liposomes Drug Delivery Market Size and Volume Forecast by Type
11.7.1. Liposomal Doxorubicin
11.7.2. Liposomal Amphoteracin B
11.7.3. Liposomal Paclitaxel
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Liposomes Drug Delivery Demand Share, 2019-2026
12. Asia Pacific Liposomes Drug Delivery Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Liposomes Drug Delivery Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Liposomes Drug Delivery Market Size and Volume Forecast by Application
12.4.1. Fungal Infection Therapy
12.4.2. Cancer & Tumor Therapy
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Liposomes Drug Delivery Market Size and Volume Forecast by Type
12.7.1. Liposomal Doxorubicin
12.7.2. Liposomal Amphoteracin B
12.7.3. Liposomal Paclitaxel
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Liposomes Drug Delivery Demand Share, 2019-2026
13. Middle East & Africa Liposomes Drug Delivery Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Liposomes Drug Delivery Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Liposomes Drug Delivery Market Size and Volume Forecast by Application
13.4.1. Fungal Infection Therapy
13.4.2. Cancer & Tumor Therapy
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Liposomes Drug Delivery Market Size and Volume Forecast by Type
13.7.1. Liposomal Doxorubicin
13.7.2. Liposomal Amphoteracin B
13.7.3. Liposomal Paclitaxel
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Liposomes Drug Delivery Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Liposomes Drug Delivery Market: Market Share Analysis
14.2. Liposomes Drug Delivery Distributors and Customers
14.3. Liposomes Drug Delivery Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Gilead Sciences
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Pacira
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Sun Pharmaceutical
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Johnson & Johnson
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Luye Pharma
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Sigma-Tau Group
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Ipsen (Onivyde)
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. CSPC
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Teva Pharmaceutical
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Novartis
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Fudan-Zhangjiang
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook